Koss Olinger Consulting LLC Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Koss Olinger Consulting LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 52.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,518 shares of the medical equipment provider’s stock after selling 10,300 shares during the period. Koss Olinger Consulting LLC’s holdings in Zimmer Biomet were worth $856,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Key Financial Inc grew its stake in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. grew its stake in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $32,000. Grove Bank & Trust grew its stake in Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 328 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Zimmer Biomet during the second quarter valued at approximately $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Barclays reduced their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. UBS Group reaffirmed a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Finally, Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $102.70.

Zimmer Biomet Trading Down 0.4%

Shares of Zimmer Biomet stock opened at $82.46 on Friday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The firm has a market cap of $15.95 billion, a PE ratio of 21.42, a PEG ratio of 1.92 and a beta of 0.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company has a 50 day simple moving average of $87.96 and a two-hundred day simple moving average of $90.63.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same period in the previous year, the business posted $1.81 earnings per share. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.